Compare Nomura Holdings Inc (NMR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Revvity Inc — how do they compare? Nomura Holdings Inc trades at $9.49 (market cap $28.05B), while Revvity Inc trades at $152.05 (market cap $17.14B). The key difference: Nomura Holdings Inc is the larger of the two by market cap, and Nomura Holdings Inc pays the higher dividend (3.4%). Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Revvity Inc for 12 Days on average.
| NMR | RVTY | |
|---|---|---|
Market Cap | $28.05B | $17.14B |
Volume | 729,574 | 2,226,396 |
Sector | Financials | Health |
52-Week High | $10.86 | $157.36 |
52-Week Low | $6.73 | $82.26 |
Typical Hold Time | 55 Days | 12 Days |
Enterprise Value | $38.55T | $19.46B |
Dividend Yield | 3.4% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.54, down 2.45% today, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.38T in 2024 to $1.66T in 2025 and net income surging to $340.74B. Valuation metrics appear attractive with P/E of 11.29 and P/B of 1.15, while analyst consensus leans toward Hold (66.67%) with some positive momentum coverage from Zacks.
The outlook presents a mixed picture - strong profitability and reasonable valuation support upside potential, but negative operating cash flows and increasing debt-to-asset ratios pose significant risks. Recent technical weakness suggests near-term pressure, though fundamental strength could drive recovery if earnings momentum continues.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
